MarketPeel
Insider Trading Intelligence
Pricing
…
RJ

Roger Jeffs

LQDA
CHIEF EXECUTIVE OFFICER · LIQUIDIA CORP · CIK 0001231615
FILING MIX · LIFETIME45%/55%
BUYS
56
SELLS
68
TOTAL VALUE
$61.31M
COMPANIES
2
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
1,221,537
AVG SELL PX
$51.97
TRADE KIND
SHOWING 124 / 124
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
38 backtested trades · 8 horizons · 67 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Roger Jeffs, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d38+42.11%+7.31%+0.74%+6.64%+2.38%2.59
14d38+50.00%+8.88%+1.52%+2.80%-0.35%0.97
30d38+47.37%+17.97%+1.85%+15.35%+7.66%3.71
60d38+18.42%+33.06%+3.42%+29.65%+6.99%4.83
90d38(7 pending)+22.58%+35.38%+5.11%+30.27%+19.12%3.92
180d38(13 pending)+32.00%+40.03%+6.40%+33.63%+29.01%—
1y38(21 pending)+47.06%+107.63%+12.85%+86.90%+64.11%—
2y38(26 pending)+50.00%+182.61%+31.31%+151.30%+98.97%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LQDA · 1,163,170 shares · as of Jul 13, 2026
0440,795881,5901,322,3851,763,180202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 56 buys / 68 sellsCOVERAGE · 27 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
2,505$71.39$178.8K1,163,170Jul 13, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
32,744$71.52$2.34M1,130,426Jul 13, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
14,333——143,329Jul 10, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
13,834——1,151,342Jul 10, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
14,333——1,165,675Jul 10, 2026Jul 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
13,834——83,001Jul 10, 2026Jul 14, 2026 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
286$249.12$71.2K58,367Jun 11, 2026Jun 11, 2026 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
286$246.18$70.4K58,653Jun 10, 2026Jun 11, 2026 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
1,429——58,939Jun 8, 2026Jun 10, 2026 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
1,429——0Jun 8, 2026Jun 10, 2026 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,721——1,721Jun 5, 2026Jun 9, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
6,428$62.18$399.7K1,041,667May 27, 2026May 28, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$60.38$1.51M1,048,095May 26, 2026May 26, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$61.52$1.54M1,073,095May 22, 2026May 26, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$61.13$1.53M1,098,095May 21, 2026May 26, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$61.30$1.53M1,123,095May 20, 2026May 20, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$58.65$1.47M1,148,095May 19, 2026May 20, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$56.77$1.42M1,173,095May 18, 2026May 20, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$57.04$1.43M1,198,095May 15, 2026May 15, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$58.62$1.47M1,223,095May 14, 2026May 15, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$56.29$1.41M1,248,095May 13, 2026May 15, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$54.04$1.35M1,273,095May 12, 2026May 12, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$41.50$1.04M1,298,095May 11, 2026May 12, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$42.14$1.05M1,323,095May 8, 2026May 12, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$42.09$1.05M1,348,095May 7, 2026May 7, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$40.78$1.02M1,373,095May 6, 2026May 7, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$40.10$1.00M1,398,095May 5, 2026May 7, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
18,839$40.60$765.0K1,423,095Apr 17, 2026Apr 21, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$40.31$1.01M1,441,934Apr 16, 2026Apr 16, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$40.14$1.00M1,466,934Apr 15, 2026Apr 16, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
3,300$40.00$132.0K1,491,934Apr 14, 2026Apr 16, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
32,744$38.37$1.26M1,137,599Apr 13, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
14,333——1,170,343Apr 10, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
14,333——157,662Apr 10, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
13,834——96,835Apr 10, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
21,433$40.12$859.9K1,495,234Apr 10, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
13,834——1,156,010Apr 10, 2026Apr 14, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
25,000$40.12$1.00M1,516,667Apr 9, 2026Apr 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
115,344——1,152,872Jan 16, 2026Jan 21, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
173,016——173,016Jan 16, 2026Jan 21, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
66,610$37.43$2.49M1,037,528Jan 12, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
13,833——110,669Jan 9, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
57,332——171,995Jan 9, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
13,833——1,046,806Jan 9, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
57,332——1,104,138Jan 9, 2026Jan 13, 2026 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
20,261$23.41$474.3K1,032,973Oct 13, 2025Oct 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
13,834——124,502Oct 10, 2025Oct 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
13,834——1,053,234Oct 10, 2025Oct 15, 2025 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
13,464$123.68$1.67M57,510Sep 2, 2025Sep 2, 2025 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$121.27$2.43M70,974Aug 29, 2025Aug 29, 2025 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$121.60$2.43M90,974Aug 28, 2025Aug 29, 2025 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$122.30$2.45M110,974Aug 27, 2025Aug 29, 2025 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$120.03$2.40M130,974Aug 26, 2025Aug 26, 2025 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
16,694$120.08$2.00M150,974Aug 22, 2025Aug 26, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
20,252$14.28$289.2K1,038,560Jul 14, 2025Jul 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
20,252$14.28$289.2K1,038,560Jul 14, 2025Jul 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
13,833——138,336Jul 11, 2025Jul 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
13,833——1,058,812Jul 11, 2025Jul 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
13,833——138,336Jul 11, 2025Jul 15, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
13,833——1,058,812Jul 11, 2025Jul 15, 2025 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,429——1,429Jun 6, 2025Jun 10, 2025 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,166——3,166Jun 6, 2025Jun 10, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
30,610$16.97$519.5K1,044,979Jun 4, 2025Jun 5, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
69,169——1,075,589Jun 3, 2025Jun 5, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
69,169——152,169Jun 3, 2025Jun 5, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
14,130$13.57$191.7K1,006,420Apr 14, 2025Apr 16, 2025 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,408——1,408Feb 21, 2025Feb 25, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
22,343$11.78$263.2K1,019,177Jan 14, 2025Jan 14, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
229,327——229,327Jan 11, 2025Jan 14, 2025 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
229,327——1,041,520Jan 11, 2025Jan 14, 2025 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
8,053$11.11$89.5K812,193Oct 14, 2024Oct 15, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
8,053$12.53$100.9K818,932Jul 12, 2024Jul 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,799——5,799Jun 7, 2024Jun 11, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
8,360$14.58$121.9K826,985Apr 12, 2024Apr 16, 2024 ↗View →
LQDA
LIQUIDIA CORP
SALE10b5-1
10b5-1 plan
28,583$15.82$452.2K835,345Mar 18, 2024Mar 19, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
2,347——0Mar 15, 2024Mar 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
2,347$29.91$70.2K123,103Mar 15, 2024Mar 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,347$71.61$168.1K120,756Mar 15, 2024Mar 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
13,000$22.03$286.4K133,756Mar 14, 2024Mar 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
13,000$69.70$906.1K120,756Mar 14, 2024Mar 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
16,976——0Mar 14, 2024Mar 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
16,976$25.53$433.4K137,732Mar 14, 2024Mar 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
16,976$69.70$1.18M120,756Mar 14, 2024Mar 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
13,000——0Mar 14, 2024Mar 15, 2024 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,425——1,425Feb 27, 2024Feb 29, 2024 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
221,338——862,143Jan 11, 2024Jan 16, 2024 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
221,338——221,338Jan 11, 2024Jan 16, 2024 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
139,665$7.16$1.00M640,805Dec 14, 2023Dec 18, 2023 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,681——5,681Jun 2, 2023Jun 6, 2023 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,082——2,082Mar 2, 2023Mar 6, 2023 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
289,500——496,749Jan 11, 2023Jan 13, 2023 ↗View →
LQDA
LIQUIDIA CORP
SALEGRANT
Stock grant
371,154——371,154Jan 11, 2023Jan 13, 2023 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
15,807——0Jan 3, 2023Jan 5, 2023 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
15,807——207,249Jan 3, 2023Jan 5, 2023 ↗View →
LQDA
LIQUIDIA CORP
SALE
Chief Executive Officer
47,423——15,807Oct 3, 2022Oct 4, 2022 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
47,423——207,250Oct 3, 2022Oct 4, 2022 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
43,820$5.57$244.0K159,827Sep 6, 2022Sep 7, 2022 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
993$4.90$4.9K116,007Aug 31, 2022Apr 10, 2023 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
993$4.90$4.9K116,007Aug 31, 2022Sep 1, 2022 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
931,475——931,475Jun 17, 2022Jun 22, 2022 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,976——16,976Jun 3, 2022Jun 7, 2022 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
Chief Executive Officer
28,000$3.53$98.8K46,595May 24, 2022May 25, 2022 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
154,167——1,541,667Mar 31, 2022Apr 20, 2022 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,347——2,347Mar 4, 2022Mar 8, 2022 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
63,230——63,230Jan 3, 2022Jan 4, 2022 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
1,682,827——1,763,180Jan 3, 2022Jan 4, 2022 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
3,950$37.30$147.4K120,756Nov 19, 2021Nov 23, 2021 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
20,000——20,000Aug 20, 2021Sep 1, 2021 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,325——7,325Jun 4, 2021Jun 8, 2021 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
99,206$2.52$250.0K111,706Apr 13, 2021Apr 14, 2021 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
30,353——30,353Mar 24, 2021Mar 26, 2021 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,463——1,463Mar 5, 2021Mar 9, 2021 ↗View →
LQDA
LIQUIDIA CORP
PURCHASEGRANT
Stock grant
30,000——30,000Nov 18, 2020Nov 19, 2020 ↗View →
LQDA
LIQUIDIA CORP
PURCHASE
1,387,500$6.00$8.32M1,387,500Nov 18, 2020Nov 19, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,000——13,000Jun 5, 2020Jun 5, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,496——4,496Mar 17, 2020Mar 19, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
9,127——0Jan 10, 2020Jan 14, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
34,866——0Jan 10, 2020Jan 14, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
5,193$8.02$41.6K70,940Jan 10, 2020Jan 14, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
5,193——0Jan 10, 2020Jan 14, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
34,866$12.95$451.5K116,806Jan 10, 2020Jan 14, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
9,127$9.00$82.1K65,747Jan 10, 2020Jan 14, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
11,000——0Jan 10, 2020Jan 14, 2020 ↗View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
11,000$4.95$54.5K81,940Jan 10, 2020Jan 14, 2020 ↗View →
Other insiders · LQDA
Loading peer insiders…
About this filer
CIK 0001231615
ROLE
Chief Executive Officer
PRIMARY
LQDA
COMPANIES
2
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001231615DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback